Metastatic Prostate Cancer—A Review of Current Treatment . . . Simple Summary Prostate cancer is the most common tumor in men Although there have been many new developments in the last few years, metastatic castration resistant prostate cancer remains a deadly disease This article provides an overview of currently approved treatment options as well as new therapies that are not standard of care yet All relevant developments from classical androgen
Overview of the treatment of castration-resistant prostate . . . INTRODUCTION Androgen deprivation therapy with or without an androgen receptor pathway inhibitor is a usual first-line option for males with advanced prostate cancer, but the vast majority eventually progress while receiving hormonal therapies, and the disease state is referred to as castration-resistant prostate cancer (CRPC)
Expanded Treatment Options for Metastatic CRPC: ASCO . . . ASCO released an update to its guideline on systemic therapy for patients with metastatic castration-resistant prostate cancer The update provides recommendations based on a patient’s previous treatment, addresses adoption of somatic genetic testing, and discusses the advent of radiopharmaceuticals or radioligand therapies
Metastatic Prostate Cancer Treatments | Memorial Sloan . . . Another chemotherapy drug for treating castration-resistant prostate cancer is cabazitaxel (Jevtana ®) It’s also used by people with metastatic prostate cancer that has grown while they are taking docetaxel Immunotherapy for Metastatic Prostate Cancer Immunotherapy uses the power of the immune system to target cancer cells
Treatment options for metastatic castration-resistant . . . Latest metastatic castration-resistant prostate cancer (mCRPC) treatment advances In a recent webinar, Massachusetts General Hospital’s Dr Xin Gao explored the latest advancements and research in prostate cancer and key findings from 2024’s American Society of Clinical Oncology (ASCO) meeting Watch the full discussion below
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Metastatic Castration-Resistant Prostate Cancer (mCRPC) What You Should Know What is Prostate Cancer? Prostate cancer develops when abnormal cells form and grow in the prostate gland Unlike benign (or non-cancerous) growths, these are cancerous (malignant)
Treatment options for metastatic prostate cancer Treatment for prostate cancer that continues to grow or comes back Treatment often controls metastatic prostate cancer for many months to years But sometimes the cancer starts to grow again You might hear your doctor saying that you now have: castration resistant prostate cancer or hormone refractory prostate cancer This means that hormone therapy is no longer working Your treatment depends
Treatment of Hormone-Resistant Prostate Cancer | Prostate . . . It is sometimes referred to as hormone-resistant prostate cancer (HRPC) Standard hormone therapy alone is not enough for these patients, and they need to use additional treatments There is another state of prostate cancer called non-metastatic castration-resistant prostate cancer (nmCRPC)